Korea’s Mirae SCI said that it has secured financing from the Yozma Group to create a “biotechnology-focused joint venture with the Israel-based venture capital firm.” The Yozma group Korea invested $4.65 million in the form of convertible bonds, selling them for bonds worth over $7.2 million.
Yigal Erlich, AlmaLinks member and Yozma Group Chairman says that, “Yozma Bio Holdings will play a central role for our future investments in Korean biotechs.”
